L50.8 T78.4
Conditions
Interventions
Group 1: Patients with Chronic Urticaria or Allergy sufferers (allergic rhinoconjunctivitis, allergic asthma) are characterized clinically once (clinical scores for severity and activity, quality of l
Sponsors
Charité-Universitätsmedizin Berlin, Klinik für Dermatologie und Allergologie
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Healthy volunteers or Patients suffering from one of the following diseases: - Chronic urticaria - allergy sufferers (allergic rhinoconjunctivitis, allergic asthma) Furthermore: - Adult - Time of diagnosis of the disease > 3 months - For women of childbearing age: negative pregnancy test - Patients may have additional concomitant diseases, but only a dominant skin disease - No participation in other clinical trials 4 weeks before
Exclusion criteria
Exclusion criteria: Exclusion criteria: - Simultaneous/continuous treatment with immunosuppressants (e.g. cyclosporine, methotrexate, dapsone or others) within 4 weeks or 5 half-lives prior to study start, whichever is longer - Simultaneous/continuous treatment with omalizumab, dupilumab or other "Biologics" within 3 months before start of study - breast-feeding or pregnant women - Participation in another study with an investigational drug; participation less than 4 weeks or 5 half-lives of the investigational drug, whichever is longer - Persons who have concerns about compliance with the study procedure - Any disease which, in the opinion of the investigator, would impair participation in the study or put the person at risk - Persons who are officially or legally detained in a public facility - Taking leukotriene antagonists within 7 days of study initiation - History of drug abuse (drugs or alcohol) or other factors (e.g. severe psychiatric illness) that may limit the subjects' ability to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The autoreactive IgE will be characterized better with regard to their antigen recognition and the different cell activation patterns (cytokinergicity) compared to exo-allergenic IgE will be determined. Participants will undergo once blood drawing, physical examination and will answer questionnaires regarding their disease. | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation of autoreactivity of IgE against autoantigens with disease activity, duration of disease and pathological relevance. | — |
Countries
Germany
Contacts
Public ContactSabine Altrichter
Charite-Universitätsmedizin Berlin, Klinik für Dermatologie und Allergologie
Outcome results
None listed